1. Home
  2. SVRA vs DNTH Comparison

SVRA vs DNTH Comparison

Compare SVRA & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SVRA
  • DNTH
  • Stock Information
  • Founded
  • SVRA 2007
  • DNTH 2015
  • Country
  • SVRA United States
  • DNTH United States
  • Employees
  • SVRA N/A
  • DNTH N/A
  • Industry
  • SVRA Biotechnology: Pharmaceutical Preparations
  • DNTH Biotechnology: Pharmaceutical Preparations
  • Sector
  • SVRA Health Care
  • DNTH Health Care
  • Exchange
  • SVRA Nasdaq
  • DNTH Nasdaq
  • Market Cap
  • SVRA 528.3M
  • DNTH 568.6M
  • IPO Year
  • SVRA N/A
  • DNTH N/A
  • Fundamental
  • Price
  • SVRA $2.21
  • DNTH $18.85
  • Analyst Decision
  • SVRA Buy
  • DNTH Strong Buy
  • Analyst Count
  • SVRA 5
  • DNTH 8
  • Target Price
  • SVRA $5.60
  • DNTH $53.00
  • AVG Volume (30 Days)
  • SVRA 1.2M
  • DNTH 312.2K
  • Earning Date
  • SVRA 08-11-2025
  • DNTH 08-07-2025
  • Dividend Yield
  • SVRA N/A
  • DNTH N/A
  • EPS Growth
  • SVRA N/A
  • DNTH N/A
  • EPS
  • SVRA N/A
  • DNTH N/A
  • Revenue
  • SVRA N/A
  • DNTH $6,524,000.00
  • Revenue This Year
  • SVRA N/A
  • DNTH N/A
  • Revenue Next Year
  • SVRA N/A
  • DNTH N/A
  • P/E Ratio
  • SVRA N/A
  • DNTH N/A
  • Revenue Growth
  • SVRA N/A
  • DNTH 102.36
  • 52 Week Low
  • SVRA $1.89
  • DNTH $13.37
  • 52 Week High
  • SVRA $5.11
  • DNTH $32.27
  • Technical
  • Relative Strength Index (RSI)
  • SVRA 41.30
  • DNTH 53.29
  • Support Level
  • SVRA $1.98
  • DNTH $17.27
  • Resistance Level
  • SVRA $2.29
  • DNTH $19.46
  • Average True Range (ATR)
  • SVRA 0.14
  • DNTH 1.05
  • MACD
  • SVRA 0.02
  • DNTH 0.14
  • Stochastic Oscillator
  • SVRA 42.19
  • DNTH 72.45

About SVRA Savara Inc.

Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.

About DNTH Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

Share on Social Networks: